Clareo Health | A Study to Learn About the Amount of the Study Medicine (Sisunatovir) in Blood and Its Safety in Infants and Children With Pneumonia Caused by RSV
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
0–5
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1 day to ≤60 months of age and weight ≥2.5 kg to ≤23 kg
Positive RSV diagnostic test, antigen or molecular test
Evidence of Lower Respiratory Tract Infection (LRTI)
You may not be if
Premature infants (gestational age less than 35 weeks) AND \<1 year of post-natal age
Neonates with intrauterine growth restriction
Expected to receive an antiviral for another viral infection within 10 days of screening
Suspected or confirmed clinically significant moderate or severe bacterial infection that may interfere with the evaluation of response to the study intervention
Known to have significant comorbidities that would limit the ability to administer the study intervention or evaluate the safety or clinical response to the study intervention
